AI Article Synopsis

  • p53 inhibits cell growth and promotes cell death (apoptosis), while Mdm2 and Mdm4 block p53's effects during embryonic development.
  • Conditional inactivation of Mdm2 specifically in smooth muscle cells (SMCs) led to severe health issues and death in mice, highlighting the critical role of Mdm2 in regulating p53 activity.
  • The study revealed that Mdm2 prevents p53 accumulation in resting SMCs, preventing an alternative form of cell death that doesn't involve caspase-3, thus showcasing the complexity of p53 regulation in quiescent cells.

Article Abstract

p53 is a potent inhibitor of cell growth and an inducer of apoptosis. During embryonic development, Mdm2 and Mdm4 inhibit the growth suppressive activities of p53. However, whether tight surveillance of p53 activity is required in quiescent cells is unknown. To test this, conditional inactivation of mdm2 and mdm4 was carried out in smooth muscle cells (SMCs). Upon SMC-specific inactivation of mdm2, and not of mdm4, mice rapidly became ill and died. Necropsy showed small intestinal dilation, and histological analyses indicated a severe reduction in the number of intestinal SMCs. Increased p53 levels and activity were detected in the remaining SMCs, and the phenotype was completely rescued on a p53-null background. Interestingly, intestinal SMCs are caspase-3-negative and therefore did not undergo caspase-3-dependent apoptotic cell death. Together, Mdm2, but not Mdm4, prevents accumulation of active p53 in quiescent SMCs and thereby the induction of p53-mediated caspase-3-independent cell death.

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.cdd.4401973DOI Listing

Publication Analysis

Top Keywords

mdm2 mdm4
20
cell death
12
smooth muscle
8
muscle cells
8
p53-mediated caspase-3-independent
8
caspase-3-independent cell
8
inactivation mdm2
8
intestinal smcs
8
mdm2
5
p53
5

Similar Publications

Background: The metastasis-promoting G-protein-coupled receptor CXC Receptor 4 (CXCR4) is activated by the chemokine CXCL12, also known as stromal cell-derived factor 1 (SDF-1). The CXCL12/CXCR4 pathway in cancer promotes metastasis but the molecular details of how this pathway cross-talks with oncogenes are understudied. An oncogene pathway known to promote breast cancer metastasis in MDA-MB-231 xenografts is that of Mouse Double Minute 2 and 4 (MDM2 and MDM4, also known as MDMX).

View Article and Find Full Text PDF

Rituximab combined with systemic chemotherapy significantly improves the rate of complete response in B-cell lymphomas. However, acquired rituximab resistance develops in most patients leading to relapse. The mechanisms underlying rituximab resistance are not well-understood.

View Article and Find Full Text PDF

MDM4 exon skipping upon dysfunctional ribosome assembly.

Trends Cell Biol

November 2024

Department of Molecular Oncology, Göttingen Center of Molecular Biosciences (GZMB), University Medical Center Göttingen, Justus-von-Liebig-Weg 11, 37077 Göttingen, Germany; Max Planck Institute for Multidisciplinary Sciences, Am Fassberg 11, 37077 Göttingen, Germany. Electronic address:

Recent studies revealed how nucleolar stress enhances MDM4 exon skipping and activates p53 via the ribosomal protein L22 (RPL22; eL22). Tumor-associated L22 mutations lead to full-length MDM4 synthesis, overcoming tumor suppression by p53. This forum article explores how MDM4 splicing patterns integrate stress signaling to take p53-dependent cell fate decisions.

View Article and Find Full Text PDF

An update patent review of MDM2-p53 interaction inhibitors (2019-2023).

Expert Opin Ther Pat

December 2024

Institute of Molecular and Industrial Biotechnology, Lodz University of Technology, Lodz, Poland.

Article Synopsis
  • The p53 tumor suppressor protein is commonly disrupted in cancers through TP53 mutations or MDM2 overexpression, leading to interest in inhibitors that can release p53 for cancer therapy.
  • The article reviews patents and patent applications from 2019 to 2023 for MDM2-p53 interaction inhibitors, categorizing newly discovered compounds into five groups based on their chemical structure.
  • Despite two decades of research and various clinical evaluations, no MDM2-p53 inhibitors have been approved for market use yet, though over ten are still undergoing clinical trials, including some with promising FDA designations.
View Article and Find Full Text PDF
Article Synopsis
  • * Research shows that Mdmx plays an anti-invasive role by stabilizing and activating the RhoA GTPase, especially in the context of NEDD8 pathway inhibitors during cell migration in Xenopus embryos.
  • * The study identifies that while Mdmx promotes RhoA activation, prolonged inhibition of NEDDylation leads to Mdmx degradation by non-NEDDylated Culin4A and the Mdm2 E3-ligase, impacting its anti-invasive effects and hinting at its importance in the effectiveness of NEDD8 pathway inhibitors in
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!